Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis - Wikidata - thesis-toulmin - TriplyDB

Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis

Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis

http://www.wikidata.org/entity/Q35843398

about

Tumor metastasis to bone A comprehensive manually curated reaction map of RANKL/RANK-signaling pathway The role of RANK-ligand inhibition in cancer: the story of denosumab RANK-RANKL signalling in cancer Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma Can heparins stimulate bone cancer stem cells and interfere with tumorigenesis?Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences Key roles of the OPG-RANK-RANKL system in bone oncology Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats Disrupted bone remodeling leads to cochlear overgrowth and hearing loss in a mouse model of fibrous dysplasia.Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases.Mesomelia-synostoses syndrome results from deletion of SULF1 and SLCO5A1 genes at 8q13.Pathway-based association analyses identified TRAIL pathway for osteoporotic fractures.Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice Osteoclast formation and function in pigmented villonodular synovitis.A Follow-up Association Study of Genetic Variants for Bone Mineral Density in a Korean Population.Bisphosphonates regulate cell proliferation, apoptosis and pro-osteoclastic expression in MG-63 human osteosarcoma cells.Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer.Gs G protein-coupled receptor signaling in osteoblasts elicits age-dependent effects on bone formation.Thermally induced osteocyte damage initiates a remodelling signaling cascade.Contributions of human tissue analysis to understanding the mechanisms of loosening and osteolysis in total hip replacement.Homing of cancer cells to the bone Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.Interruption of Electrical Conductivity of Titanium Dental Implants Suggests a Path Towards Elimination Of Corrosion.Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.Rheumatic diseases: the effects of inflammation on bone.Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.The effects of lung and prostate cancer bone metastasis on serum osteoprotegerin levels: a meta-analysis.Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases.Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand.The role of tumor microenvironment in prostate cancer bone metastasis.Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.OPG rs2073617 polymorphism is associated with upregulated OPG protein expression and an increased risk of intervertebral disc degeneration RANKL/RANK/OPG: key therapeutic target in bone oncology.Differential patterns of receptor activator of nuclear factor kappa B ligand/osteoprotegerin expression in human periapical granulomas: possible association with progressive or stable nature of the lesions.Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma.Osteolysis around total knee arthroplasty: a review of pathogenetic mechanisms.

P2860

Q21195416-DEF29535-BF4B-4B84-BC10-8132CF526FA9 Q24599024-AC9DBE43-909D-4EE4-90B5-D5538D744FF9 Q24633284-817010FF-D4A8-4325-990C-C96A1240949C Q26747442-30158A17-FFBC-4F06-9BC2-55AF1382FA3D Q26771376-331CA629-D927-46CB-BA81-206D5053EBB7 Q26852760-1C3296EB-3F33-48C4-AE6A-33D4B1AF2DA0 Q26863493-A2733144-098B-42A5-8947-4E2EF47B55BE Q28287394-589D0739-2120-4718-925E-57504B509EFA Q28575953-409ED486-650E-4FA5-9DF8-14D00B6B2233 Q28578007-71A13AC5-26C6-4851-93E2-BE2624CB3703 Q30438714-E3F9E960-44B2-4904-B6E4-600988D04CE7 Q33293423-BCE7C3DF-3C6D-41B0-829F-E34E6E3F7124 Q33960453-45D29D6D-2219-4E47-A799-230060B38B22 Q33961554-A2192355-89D3-4CD6-A72E-200B2DEE4B87 Q34090139-9D5D6D03-CD1F-4BF5-8C40-F2CF963CEF88 Q34195543-15D70994-C947-4526-8A85-4D4886AE1BD3 Q34335418-6B0F5267-B434-4C6A-98E3-B9447FB9F2A4 Q34356336-DE5E4020-9172-4F96-A360-14FC72373740 Q34629549-B6B2A524-3280-405B-96AC-C9ECBEF7AF2B Q35156288-89639084-5C54-4766-8D48-0145A532344E Q35191566-372F76A2-1DC7-443B-AF3A-7605C611CCA2 Q35317316-986AA7F9-DA90-4160-AEB2-B00E6D62B2F4 Q35603135-5E65811C-1312-4468-8C59-3AD944F07F86 Q35769514-991435CE-9968-41A6-A3F0-3F90B1925A18 Q35804788-D3E46EEC-9E1A-4EAD-A14E-A3DF3C1FB822 Q36013086-E2D68676-EA56-46EB-80AE-DE72334DB945 Q36324975-AFAAFBE7-9BC6-4F35-A994-6C6ABD913BAB Q36366450-7E6AA49F-6ECD-44DA-B194-577EF1CBE51B Q36376105-C615A4ED-6161-4232-ACB0-0668D4CEA4C6 Q36491383-2D7DA077-8DBA-442E-9895-C7FA2FCE3AF5 Q36491545-74DB9F56-113C-44FB-86FC-70A10B101555 Q36617148-211BE48B-820B-4FD0-9809-B883A510081A Q36771551-C1BB4E5A-D415-405C-89E4-2A62425F11A6 Q36860987-8C0CAAD7-F009-4B45-8929-D627067D4BE9 Q36891815-B5F9933B-6139-45C4-81B4-725641A364AE Q37107900-34FD62AA-C923-4A1B-BC6A-BCA3C8801C30 Q37140665-86F219D8-D372-4094-AEF7-23CFF7B37BB5 Q37286024-937179BD-8F49-4AAF-AA0E-5238C76263C2 Q37694632-2CB97271-E0E3-4433-B63F-521257777509 Q37730881-6FD8686A-84A8-4FEB-9E17-CDC76816F99E

P2860

Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis

http://www.wikidata.org/entity/Q35843398

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Receptor activator of nuclear ...... increased in severe osteolysis

@ast

Receptor activator of nuclear ...... increased in severe osteolysis

@en

type

label

Receptor activator of nuclear ...... increased in severe osteolysis

@ast

Receptor activator of nuclear ...... increased in severe osteolysis

@en

prefLabel

Receptor activator of nuclear ...... increased in severe osteolysis

@ast

Receptor activator of nuclear ...... increased in severe osteolysis

@en

P1433

Q35843398-38DCA91F-169C-4492-BB7F-E0A0AB5CD3C9

P1476

Q35843398-E148834F-3F13-4AAB-B217-727B48B3E1A8

P2093

Q35843398-09A05E7F-3D20-4DBE-A120-2EB3B18AD987

Q35843398-0D22E048-A7CC-4B6C-8687-34EB9B6D6689

Q35843398-9D5F5E12-AB7D-47D8-802E-4455D273326F

Q35843398-ACC39B6A-41E7-448B-8F6F-81528B3F2DA5

Q35843398-C9C8DD54-AF3C-4511-ACED-25E19C4481DA

Q35843398-D4C524AA-AD88-4402-A67E-5849567D0A77

Q35843398-E54FAEA5-3279-489E-801D-3A5952B1F95E

Q35843398-F0DD040C-A58D-411F-81DA-9F3102FC2B84

P2860

Q35843398-046D472A-A2C5-4AC8-AC80-0D01EDE5B38F

Q35843398-0D369239-B870-41D6-BAD0-E3695220DA1D

Q35843398-0D9EB165-2377-4F43-BE1D-FD69C5427542

Q35843398-147DA0E8-54AA-49DD-8646-7EBAA704C1E2

Q35843398-174D7330-C710-4926-BA24-40F8A42FF68F

Q35843398-1AB32AA9-1BBB-4152-8459-5CE3865AD1D0

Q35843398-253000A3-8079-4AB8-A379-23E5019690CD

Q35843398-2890DA05-A115-4DF6-BEFF-F49FFE8059C4

Q35843398-2980C2DA-39A2-4102-A63E-2CA0F270BE85

Q35843398-2C16A67C-7080-4C6D-AC46-CA91327B27C1

P304

Q35843398-9C5F73FC-0302-41BC-B450-28927AC995D9

P31

Q35843398-8D20BC8D-88CA-4AB9-876A-8388EA44C981

P356

Q35843398-79CFB0FB-2FFA-468F-8E63-62900E31A9E6

P407

Q35843398-42A4D1CB-1063-44D8-AC8B-EF0F397C414F

P433

Q35843398-A656FFBD-B1FD-4342-B18E-DEEFA619CB3F

P478

Q35843398-4990F2CA-6F50-4B7C-8462-FACC38BD105E

P50

Q35843398-0825A725-14E3-47BA-9935-BC27D1D676D1

P577

Q35843398-15E56635-02BF-4994-9633-A4274CE54E98

P698

Q35843398-99D0311E-1724-4258-896D-55517577A553

P932

Q35843398-2581F4AC-E5C4-4323-9605-A593B269C545

P356

S0002-9440(10)63560-2

P1433

The American Journal of Pathology

P1476

Receptor activator of nuclear ...... increased in severe osteolysis

@en

P2093

Anne Moreau

http://www.w3.org/2001/XMLSchema#string

Eva Grimaud

http://www.w3.org/2001/XMLSchema#string

François Gouin

http://www.w3.org/2001/XMLSchema#string

Françoise Redini

http://www.w3.org/2001/XMLSchema#string

Luc Soubigou

http://www.w3.org/2001/XMLSchema#string

Norbert Passuti

http://www.w3.org/2001/XMLSchema#string

Patrick Coipeau

http://www.w3.org/2001/XMLSchema#string

Séverine Couillaud

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

RANK-L and RANK: T cells, bone loss, and mammalian evolution

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

Wear Debris in Total Joint Replacements.

P304

2021-2031

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0002-9440(10)63560-2

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

163

http://www.w3.org/2001/XMLSchema#string

P50

Dominique Heymann

P577

2003-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14578201

http://www.w3.org/2001/XMLSchema#string

P932

1892410

http://www.w3.org/2001/XMLSchema#string